Should a Small Research Organization Choose REDCap, a Hosted EDC, or Cloud Data Storage?

October 24, 2026 · 6 min read

Choose institutional REDCap when its governance and export process fit a modest academic study; choose a hosted EDC when the study needs controlled eCRFs, source traceability, and inspection-ready audit trails; choose an organization-managed cloud environment for retained, reusable data rather than as a substitute for clinical data capture. Data ownership is proved by a complete, usable exit package, not by a login or a CSV export.

The apparent paradox is that the system with the most visible interface is not necessarily the system that best preserves a study's future. An electronic data capture system is built to collect and review study data during operations. A clinical data repository preserves governed records. A data warehouse organizes retained data for analysis and reuse. These can connect, but they do not perform the same job.

Does owning clinical trial data mean owning the platform or just receiving a complete export?

Owning clinical trial data means being able to retain, interpret, inspect, and reuse it without continued dependence on the platform; it does not mean owning the vendor's software. The practical test is blunt: after access ends, can the organization reconstruct what was collected, how the study was configured, who changed records, and what the records mean?

A flat CSV answers only part of that question. The Yale REDCap transfer guidance distinguishes project data from project metadata, meaning the design and configuration that make data intelligible in the original project. It also warns that a REDCap XML export does not include logging history, so a transfer involving data should separately include the All Logging CSV. That is a useful model for every platform exit, whether or not the study uses REDCap.

Exit-package component	Why it matters
Study data	Preserves the recorded values for analysis and retention.
Metadata and configuration	Explains forms, fields, validation, and project design.
Uploaded files and signatures, where applicable	Preserves records that do not live in the tabular export.
Audit history	Preserves the record of creation, modification, and deletion activity.
System and process documentation	Helps a later reviewer understand provenance and controls.

For FDA-regulated work, this is not archival fussiness. FDA's October 2024 guidance states that audit trails must capture changes to an electronic record, the people making them, and their date and time; it also addresses reasons for changes and says audit-trail documentation must be available for inspection. A vendor exit clause should therefore specify deliverables, format, timing, and access to the audit record, rather than merely promising that data are exportable.

Should a small nonprofit use REDCap, a commercial EDC, or build a cloud database?

A small nonprofit should start with the least complex option that can meet its study's operating and retention requirements: institutional REDCap for suitably governed studies, a commercial EDC for protocol-driven clinical operations, and a cloud environment for governed retention and reuse. Building a cloud database is a governance commitment, not a cheaper spelling of “buy.”

REDCap Consortium describes REDCap as a secure web application for online surveys and databases, with authentication, data logging, audit trails, user-management controls, multisite access, and exports to common research and statistical formats. It is available at no cost to Consortium Partners, making it a credible starting point where a university or institutional partner provides access. But REDCap's statement that it can be installed for HIPAA, 21 CFR Part 11, FISMA, and international standards is conditional on installation and governance. The software is not the compliance program.

A commercial hosted EDC earns its place when the study needs a system designed around electronic case-report forms, controlled collection and review, and a documented operational relationship with a provider. The FDA's electronic source-data guidance focuses on reliability, quality, integrity, and traceability from electronic source through regulatory submission. That emphasis creates a dividing line: a repository can retain data, but it does not automatically supply controlled source-to-eCRF processes.

A cloud data environment is strongest after or alongside collection. It can hold exports and associated documentation for analysis, controlled reuse, and long-term retention when the organization can operate the controls itself. NIH's Data Management and Sharing Policy, effective January 25, 2023, applies to NIH-funded or NIH-conducted research that generates scientific data regardless of funding level and expects a Data Management and Sharing Plan. NIH defines the relevant data as data sufficient to validate and replicate findings. Retention planning must therefore extend beyond keeping an account active.

When does a clinical study need an EDC rather than a data warehouse?

A clinical study needs an EDC rather than a data warehouse when it must control the capture, review, and traceability of study records during conduct, especially when FDA-regulated electronic source data and eCRFs are involved. A warehouse is an analytical and retention layer; it is not, by itself, evidence that the collection process was controlled.

The distinction becomes concrete when reviewing a record. FDA guidance addresses authorized source-data originators, data-element identifiers for audit-trail review, capture into eCRFs, investigator retention responsibilities, and computerized-system descriptions. Those are operational properties of the study workflow. A warehouse can receive a governed copy after collection, but loading data into one does not recreate missing source provenance or a missing audit trail.

Control also has a staffing dimension. NIAID's April 2025 requirements call for role- and privilege-based access under least privilege, named ownership of user accounts, documented training and authorization, and documented processes to grant, change, revoke, and periodically review access. They also require metadata identifying the person or system that generated data; device-originated data need supporting details such as device version, identifier, firmware version, calibration, originator, and event timestamp.

The decision rule follows. If the organization cannot continuously operate those controls in AWS or Azure, cloud storage should receive controlled exports rather than become the live clinical-capture system. If the study does not need that degree of regulated capture control, institutional REDCap may be sufficient, provided local administrators can explain the deployment, permissions, retention, and export procedure. The correct architecture is often two layers: an EDC or REDCap instance for collection, then a governed repository for retention and reuse.

Before selecting a platform, make the exit package an acceptance criterion, assign a named owner for access and retention procedures, and test an export before the study has irreplaceable data. The critical asset is not the application. It is the evidence chain that lets a future team understand and defend the dataset.

Frequently Asked Questions

Can a hosted EDC meet data ownership and future-study reuse requirements?

Yes, if the contract and operating process provide a complete export that remains intelligible outside the vendor application. Require the study data, configuration metadata, applicable uploaded files and signatures, and audit history; Yale REDCap guidance specifically notes that XML project exports omit logging history. For reuse, retain documentation that explains the fields, permissions, and provenance rather than treating a flat file as the whole study.

What internal IT skills are required to manage clinical data in AWS or Azure?

The organization must be able to operate access control, preserve traceable records, document procedures, and maintain the environment over time. NIAID requires role-based least-privilege access, named account ownership, documented training and authorization, and processes to grant, modify, revoke, and review access. The question is therefore not whether a team can create cloud storage, but whether it can continuously govern the people, configurations, records, and documentation around it.

Which compliance controls should a small study require from an EDC provider?

For an FDA-regulated study, require audit trails that record changes, the person making each change, and the date and time, with the reason for change where applicable. Require traceable user accounts, role-based least privilege, documented training, controlled access changes, record retention, and a practical inspection and export process. FDA guidance also says audit-trail documentation for creation, modification, and deletion must be available for inspection.

Sources

Written and reviewed by the Search Hole Editorial Team. Learn how we create content.